Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Business Wire•12/11/2026•16:05 ET
0
Key Highlights
- ➤Amsoki-cel achieved 67% ORR in 15 advanced melanoma patients
- ➤Amsoki-cel median PFS reached 8.3 months; median DOR not reached
- ➤Agni-01 registration-enabling enrollment expected complete by Q1 2027
- ➤Obsidian held $324.4 million cash and securities, runway into 2H 2028
- ➤Obsidian reported $50.7 million third-quarter net loss, or $1.23 per share
Expert Statements
Madan Jagasia, M.D., Chief Executive Officer of Obsidian Therapeutics
“2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350 million financing, completed our transaction with Galera Therapeutics, and debuted on Nasdaq as a publicly traded company.”
Madan Jagasia, M.D., Chief Executive Officer of Obsidian Therapeutics
“We have made substantial progress advancing amsoki-cel, with enrollment ongoing in the registration-enabling immune checkpoint inhibitor-resistant advanced melanoma cohort of our Agni-01 study. The updated data we presented at SITC further strengthen our belief in the program, highlighting amsoki-cel’s consistent, favorable safety profile and encouraging clinical activity in patients with advanced melanoma, including an objective response rate of 67%, median progression-free survival of 8.3 months, and median duration of response not yet reached at median study follow-up of 14.3 months. We remain on track to complete enrollment in the registration-enabling cohort by the end of the first quarter of 2027 and report topline data by year-end 2027.”
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
* Presented positive updated efficacy and pooled safety data on amsoki-cel in advanced melanoma at the 41st Annual SITC Meeting, including a 67% ORR (n=10/15), median PFS of 8.3 months and median DOR not yet reached at 14.3 months median study follow-up
Get started
Create a free account to read the full story.